Non-selective beta-blockers, unlike cardio-selective ones, markedly reduce Tpeak/end in LQT1 patients, indicating decreased repolarization heterogeneity and reduced arrhythmic risk.
Do non-selective beta-blockers reduce Tpeak/end on ECG compared to cardio-selective beta-blockers in patients with long QT syndrome type 1?
Non-selective beta-blockers reduce Tpeak/end in LQT1 patients, suggesting decreased global repolarization heterogeneity and arrhythmic risk, and highlighting Tpeak/end as a potential marker for beta-blocker efficacy.
Absolute Event Rate: 0% vs 0%
•Non-selective β-blockers markedly reduce Tpeak/end in LQT1 patients.•Cardio-selective β-blockers show no consistent effect on Tpeak/end.•The nsBB effect persists after exercise, independent of heart rate.•Tpeak/end shortening indicates decreased global repolarization heterogeneity and reduced arrhythmic risk.•Tpeak/end may serve as a novel ECG marker for β-blocker efficacy in LQT1.
Rieder et al. (Mon,) reported a other. Non-selective beta-blockers, unlike cardio-selective ones, markedly reduce Tpeak/end in LQT1 patients, indicating decreased repolarization heterogeneity and reduced arrhythmic risk.